BPC-157 research: what the published literature shows
Three decades of animal data, a thin slice of early human work, and a regulatory picture that is still moving.
TL;DR
- The BPC-157 research base is mostly animal: tendon healing, intestinal damage, and wound models.
- Mechanism work points to angiogenesis (new blood vessel formation) and nitric oxide signaling.
- Large human trials are limited. Anyone reading marketing claims should know the difference between animal and human evidence.
What it is
BPC-157 stands for Body Protective Compound 157. It is a synthetic peptide that copies a 15-amino-acid stretch of a protein found in human stomach juice. Most of the published research has been led by Predrag Sikiric's group in Croatia, and the literature now spans more than thirty years (Sikiric et al., Current Pharmaceutical Design, 2014).
How it works
The proposed mechanism, in plain English: BPC-157 appears to help the body build new small blood vessels and direct repair cells to the right place. The technical names are angiogenesis and nitric oxide signaling. Picture a road crew at a pothole — new supply lines and active dispatchers. Animal studies have linked BPC-157 to both jobs (Gwyer et al., Cell and Tissue Research, 2019).
Who asks about it
People usually arrive at BPC-157 from a recovery, gut-health, or sports-medicine context. The questions that follow are practical: what has been studied, in what species, and how well does the evidence hold up? That is what this post answers.
What the research says
The animal literature covers several recurring themes. Tendon-to-bone healing in rats. Intestinal damage and colitis-like models. Brain-gut signaling work, often using the vagus nerve as a path. Wound healing and bone repair models. Across these settings, the mechanism story is consistent: angiogenesis, nitric oxide signaling, and faster recovery in the treated animals (Gwyer et al., 2019).
Human research is much thinner. There are early-phase safety reports and small pilot studies in the literature, but no large randomized controlled trials. That is the honest line.
What to know before considering it
BPC-157 is currently on the FDA's Category 2 list. That means it cannot be prepared by 503A compounding pharmacies in the United States. Any clinician conversation about BPC-157 has to start with the regulatory reality. Side effects in the available human literature appear limited, but the human sample size is small.
The Halftime POV
There is a real research base here, and there is also a wide gap between what has been shown in rodents and what has been shown in people. We treat both as true at the same time. When the human evidence improves — or the regulatory picture changes — we will say so without dressing it up.
Related reading:
- BPC-157: what this body protection compound is
- How BPC-157 promotes tissue repair: the mechanism
- BPC-157 human trials: what has actually been studied
FAQ
Q: What has BPC-157 been studied for? A: Most of the published BPC-157 work is in animals. Studies cover tendon healing, intestinal damage models, brain-gut signaling, and wound healing. Human clinical trial data is limited.
Q: Is there human research on BPC-157? A: There are a small number of early human safety and pilot studies in the published literature, but no large randomized trials. The honest line is that the evidence base is mostly animal-driven.
Q: Is BPC-157 FDA-approved? A: No. BPC-157 is not FDA-approved. As of 2026 it sits on the FDA's Category 2 list and is not currently available from 503A compounding pharmacies.
Disclaimer
As of May 2026, BPC-157 is classified by the FDA as Category 2, which means it is not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157. Current Pharmaceutical Design, 2014.
- Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019.
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What has BPC-157 been studied for?
Most of the published BPC-157 work is in animals. Studies cover tendon healing, intestinal damage models, brain-gut signaling, and wound healing. Human clinical trial data is limited.
Is there human research on BPC-157?
There are a small number of early human safety and pilot studies in the published literature, but no large randomized trials. The honest line is that the evidence base is mostly animal-driven.
Is BPC-157 FDA-approved?
No. BPC-157 is not FDA-approved. As of 2026 it sits on the FDA's Category 2 list and is not currently available from 503A compounding pharmacies.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.